U.S. braces for severe mpox strain amid rising deaths in Africa

The U.S. is preparing for the potential arrival of a more severe strain of mpox, known as clade 1, which has resulted in over 600 deaths in Africa this year. The World Health Organization reported nearly 25,000 cases of clade 1 in Africa, with significant outbreaks in the Democratic Republic of Congo and surrounding regions. This strain is more lethal than the previously known clade 2, with a mortality rate that can reach up to 10%, although recent figures indicate a death rate between 1% and 3.3%. In response to the rising cases, U.S. officials have been enhancing surveillance efforts, particularly through wastewater analysis, and are educating healthcare providers on the characteristics and transmission of clade 1. Testing capabilities are being expanded, allowing any doctor in the U.S. to order mpox tests through national laboratories. If clade 2 is ruled out, a presumptive diagnosis of clade 1 can be made, pending confirmation from the CDC. The Jynneos vaccine, effective against both clade 1 and clade 2, is available for high-risk individuals, primarily gay and bisexual men, at no cost through public health departments. Officials have assured that there is a sufficient vaccine supply in the national stockpile, although specific quantities have not been disclosed. Additionally, the U.S. is collaborating with scientists and pharmaceutical companies to explore new treatment options. While TPOXX, an antiviral approved for smallpox, has been found ineffective against clade 1, efforts continue to develop effective therapies for this emerging health threat.